Work

Therapeutic response and outcomes with less common breast cancer subtypes in the I-SPY trial 2011-2022.

Year: 2024

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2024.42.16_suppl.582

Authors: Alexandra Thomas, Denise M. Wolf, Ronald Balassanian, Yunn-Yi Chen, Julia Ye, Poonam Vohra, Evin H Gulbahce, Alexander D. Borowsky, Lamorna Brown Swigart, Gillian L. Hirst, Sara Venters, Rita Nanda, Rebecca Arielle Shatsky, Ralph D'Agostino, Rita A. Mukhtar, Sarah Hatcher, Christina Yau, Angela DeMichele, Laura van 't Veer, Laura Esserman

Institutions: Duke University, Duke Cancer Institute, University of California, San Francisco, University of Utah, University of California, Davis, University of Chicago, University of California San Diego, Wake Forest University Health Sciences, Wake Forest University, University of Pennsylvania

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4399123748

Cites:

Cited by: 1

Related to: 10